Teva Pharmaceutical Industries Stock Price, Forecast & Analysis (NYSE:TEVA)

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced its earnings results on Thursday, November, 7th. The company reported $0.56 earnings per share for the quarter, missing the consensus estimate of $0.58 by $0.02. The business had revenue of $4.26 billion for the quarter, compared to analyst estimates of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 15.41% and a negative net margin of 22.88%. View Teva Pharmaceutical Industries' Earnings History.

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries issued an update on its FY19 earnings guidance on Thursday, November, 7th. The company provided earnings per share (EPS) guidance of $2.30-2.50 for the period, compared to the Thomson Reuters consensus estimate of $2.38. The company issued revenue guidance of $17.2-17.4 billion, compared to the consensus revenue estimate of $17.17 billion.

24 analysts have issued 1-year price objectives for Teva Pharmaceutical Industries' shares. Their forecasts range from $6.00 to $20.00. On average, they expect Teva Pharmaceutical Industries' stock price to reach $10.23 in the next year. This suggests that the stock has a possible downside of 1.1%. View Analyst Price Targets for Teva Pharmaceutical Industries.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 4 sell ratings, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.

Media headlines about TEVA stock have trended extremely negative on Tuesday, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a coverage optimism score of -4.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Teva Pharmaceutical Industries.

Some companies that are related to Teva Pharmaceutical Industries include Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF) and Elanco Animal Health (ELAN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Bank of America (BAC), Intel (INTC), Gilead Sciences (GILD), CVS Health (CVS) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries' stock is owned by a number of of institutional and retail investors. Top institutional investors include Commerzbank Aktiengesellschaft FI (0.80%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.49%), Sumitomo Mitsui Trust Holdings Inc. (0.37%), Beck Mack & Oliver LLC (0.22%), Strs Ohio (0.14%) and Great West Life Assurance Co. Can (0.05%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone, Sol J Barer and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

TEVA stock was sold by a variety of institutional investors in the last quarter, including Conning Inc., Cacti Asset Management LLC, Strs Ohio, Great West Life Assurance Co. Can, Janney Montgomery Scott LLC, SOL Capital Management CO, Sumitomo Mitsui Trust Holdings Inc. and First Allied Advisory Services Inc.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Luzich Partners Llc, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

TEVA stock was acquired by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Beck Mack & Oliver LLC, Diamond Hill Capital Management Inc., Daiwa Securities Group Inc., Dynamic Capital Management Ltd, Cetera Advisors LLC and IFM Investors Pty Ltd. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone, Sol J Barer and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TEVA stock can currently be purchased for approximately $10.34.

Teva Pharmaceutical Industries has a market capitalization of $11.29 billion and generates $18.85 billion in revenue each year. The company earns $-2,150,000,000.00 in net income (profit) each year or $2.80 on an earnings per share basis. Teva Pharmaceutical Industries employs 42,535 workers across the globe.View Additional Information About Teva Pharmaceutical Industries.

The official website for Teva Pharmaceutical Industries is http://www.tevapharm.com/.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]